{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:19:10Z","timestamp":1760080750297,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda UK Limited."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s41669-022-00349-z","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T11:02:23Z","timestamp":1662289343000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin"],"prefix":"10.1007","volume":"6","author":[{"given":"Holly","family":"Cranmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Trueman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Evers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fionn","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-9939","authenticated-orcid":false,"given":"Tanja","family":"Podkonjak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"key":"349_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/624040","volume":"2010","author":"T Tang","year":"2010","unstructured":"Tang T, et al. Peripheral T-cell lymphoma: review and updates of current management strategies. Adv Hematol. 2010;2010: 624040. https:\/\/doi.org\/10.1155\/2010\/624040.","journal-title":"Adv Hematol"},{"issue":"2","key":"349_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0145-2126(89)90134-3","volume":"13","author":"H Herbst","year":"1989","unstructured":"Herbst H, et al. Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin\u2019s disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leuk Res. 1989;13(2):103\u201316. https:\/\/doi.org\/10.1016\/0145-2126(89)90134-3.","journal-title":"Leuk Res"},{"issue":"25","key":"349_CR3","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756\u201367. https:\/\/doi.org\/10.1182\/blood-2010-05-231548.","journal-title":"Blood"},{"issue":"25","key":"349_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, T. C. L. P. International. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558.","journal-title":"J Clin Oncol"},{"key":"349_CR5","unstructured":"Haematological Malignancy Research Network (HMRN). T-cell Lymphoma. https:\/\/www.hmrn.org\/statistics\/disorders\/34. Accessed 10 Mar 2021."},{"issue":"7","key":"349_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/a:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol. 1998;9(7):717\u201320. https:\/\/doi.org\/10.1023\/a:1008265532487.","journal-title":"Ann Oncol"},{"issue":"12","key":"349_CR7","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402\u20138. https:\/\/doi.org\/10.1182\/blood-2010-09-310342.","journal-title":"Blood"},{"issue":"7","key":"349_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1080\/10428194.2017.1393671","volume":"59","author":"M Gleeson","year":"2018","unstructured":"Gleeson M, et al. Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leuk Lymphoma. 2018;59(7):1586\u201395. https:\/\/doi.org\/10.1080\/10428194.2017.1393671.","journal-title":"Leuk Lymphoma"},{"issue":"32","key":"349_CR9","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte trials. J Clin Oncol. 2012;30(32):3939\u201346. https:\/\/doi.org\/10.1200\/JCO.2012.42.2345.","journal-title":"J Clin Oncol"},{"key":"349_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma. 2017. https:\/\/www.nice.org.uk\/guidance\/ta478. Accessed 14 Aug 2020."},{"key":"349_CR11","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. ISRN Hematol. 2011;2011: 623924. https:\/\/doi.org\/10.5402\/2011\/623924.","journal-title":"ISRN Hematol"},{"issue":"Suppl 5","key":"349_CR12","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d'Amore","year":"2015","unstructured":"d\u2019Amore F, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315. https:\/\/doi.org\/10.1093\/annonc\/mdv201.","journal-title":"Ann Oncol"},{"issue":"4","key":"349_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","volume":"153","author":"CE Dearden","year":"2011","unstructured":"Dearden CE, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2011;153(4):451\u201385. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08651.x.","journal-title":"Br J Haematol"},{"key":"349_CR14","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: T-Cell Lymphomas. Version 2.2019. http:\/\/med.stanford.edu\/content\/dam\/sm\/cutaneouslymphoma\/documents\/2018_Dec_t-cell.pdf. Accessed 26 Jan 2021."},{"key":"349_CR15","doi-asserted-by":"crossref","unstructured":"Robinson M, Podjonjak T, Turner B, Field F. A survey of clinical practice for the front-line treatment of peripheral Tcell lymphoma (PTCL) in the United Kingdom. In: PCN515. Presented at: 2019-11, ISPOR Europe 2019, Copenhagen, Denmark. 2019.","DOI":"10.1016\/j.jval.2019.09.707"},{"key":"349_CR16","unstructured":"Dearden CJ, Pettengell RR, Devereux S, Cwynarski K, Whittaker S, McMillan A. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol. 2013. https:\/\/b-s-h.org.uk\/media\/2895\/t-nhl-guideline-3-8-13-updated-with-changes-accepted-v1-rg.pdf. Accessed 10 Mar 2021."},{"issue":"36","key":"349_CR17","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, et al. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. J Clin Oncol. 2017;35(36):4019\u201326. https:\/\/doi.org\/10.1200\/JCO.2017.73.8195.","journal-title":"J Clin Oncol"},{"issue":"3","key":"349_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651\u201365. https:\/\/doi.org\/10.1182\/blood-2011-04-325225.","journal-title":"Blood"},{"key":"349_CR19","doi-asserted-by":"crossref","unstructured":"Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000; 96(13): 4307\u201312. [Online]. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11110706.","DOI":"10.1182\/blood.V96.13.4307"},{"issue":"10168","key":"349_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"key":"349_CR21","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.2147\/OTT.S141053","volume":"11","author":"EM Donato","year":"2018","unstructured":"Donato EM, Fernandez-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:4583\u201390. https:\/\/doi.org\/10.2147\/OTT.S141053.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"349_CR22","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jcmm.13344","volume":"22","author":"S Schonberger","year":"2018","unstructured":"Schonberger S, et al. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. J Cell Mol Med. 2018;22(1):568\u201375. https:\/\/doi.org\/10.1111\/jcmm.13344.","journal-title":"J Cell Mol Med"},{"key":"349_CR23","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human use (CHMP) agenda for the meeting on 14-17 October 2019. https:\/\/www.ema.europa.eu\/en\/documents\/agenda\/agenda-chmp-agenda-14-17-october-2019-meeting_en.pdf. Accessed 26 Jan 2021."},{"key":"349_CR24","unstructured":"European Medicines Agency (EMA). Adcetris, INN-brentixumab vedotin. Summary of Product Characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf. Accessed 26 Jan 2021."},{"key":"349_CR25","unstructured":"National Institute for Health and Care Excellence (NICE). Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma, in Technology appraisal guidance. 2020. https:\/\/www.nice.org.uk\/guidance\/ta641\/documents\/final-appraisal-determination-document. Accessed 26 Jan 2021."},{"key":"349_CR26","unstructured":"National Institute for Health and Care Excellence. NICE NG52. Non-Hodgkin's lymphoma: diagnosis and management. 2016. [Online]. https:\/\/www.nice.org.uk\/guidance\/ng52\/evidence\/full-guideline-2551524594. Accessed 11 May 2022."},{"key":"349_CR27","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. https:\/\/www.nice.org.uk\/guidance\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 26 Jan 2021."},{"key":"349_CR28","volume-title":"NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching","author":"NR Latimer","year":"2014","unstructured":"Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. London: NICE Decision Support Unit Technical Support Documents; 2014."},{"issue":"2","key":"349_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1177\/0962280214557578","volume":"26","author":"NR Latimer","year":"2017","unstructured":"Latimer NR, et al. Adjusting for treatment switching in randomised controlled trials\u2014a simulation study and a simplified two-stage method. Stat Methods Med Res. 2017;26(2):724\u201351. https:\/\/doi.org\/10.1177\/0962280214557578.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"349_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12874-019-0709-9","volume":"19","author":"NR Latimer","year":"2019","unstructured":"Latimer NR, Abrams KR, Siebert U. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Med Res Methodol. 2019;19(1):69. https:\/\/doi.org\/10.1186\/s12874-019-0709-9.","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"349_CR31","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1177\/0962280218780856","volume":"28","author":"NR Latimer","year":"2019","unstructured":"Latimer NR, White IR, Abrams KR, Siebert U. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times? Stat Methods Med Res. 2019;28(8):2475\u201393. https:\/\/doi.org\/10.1177\/0962280218780856.","journal-title":"Stat Methods Med Res"},{"key":"349_CR32","unstructured":"National Institute for Health and Care Excellence (NICE). NICE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2013. http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed 10 Mar 2021."},{"issue":"11","key":"349_CR33","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108. https:\/\/doi.org\/10.1097\/00005650-199711000-00002.","journal-title":"Med Care"},{"issue":"6","key":"349_CR34","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","volume":"56","author":"P Swinburn","year":"2015","unstructured":"Swinburn P, Shingler S, Acaster S, Lloyd A, Bonthapally V. Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839\u201345. https:\/\/doi.org\/10.3109\/10428194.2014.970542.","journal-title":"Leuk Lymphoma"},{"key":"349_CR35","unstructured":"National Institute for Health and Care Excellence (NICE), British National Formulary (BNF). https:\/\/bnf.nice.org.uk\/. Accessed 12 June 2019."},{"key":"349_CR36","unstructured":"National Health Service (NHS), \"Reference costs\/NHS improvement. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/#rc1718. Accessed 12 Aug 2019."},{"key":"349_CR37","unstructured":"National Health Service (NHS), \"London Cancer Alliance. CHOP 21 +\/- Rituximab for Non-Hodgkin's Lymphoma (NHL) protocol. 2011. http:\/\/www.londoncanceralliance.nhs.uk\/media\/36668\/NHL_CHOP-R_Protocol_V1_1.pdf. Accessed 4 Jun 2019."},{"key":"349_CR38","unstructured":"Personal Social Services Research Unit (PSSRU), \"Unit Costs of Health and Social Care. 2018. https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/. Accessed 4 Jun 2019."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00349-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-022-00349-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-022-00349-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:40:38Z","timestamp":1666730438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-022-00349-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s41669-022-00349-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"14 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by Takeda UK Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HC is an employee of Takeda Pharmaceuticals International Co. TP is an employee of Takeda UK Limited. DT, EE, and FW are employees of Source Health Economics who received funding for this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No additional data or materials are available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The economic model used in this study is proprietary intellectual property.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HC and TP were responsible for study conception and design. DT performed the statistical analysis and prepared the first draft of this manuscript. EE and FW developed the economic model. All authors contributed to the interpretation of the results, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}